Me! I Disconnect From You

Ortho-McNeil Neurologics, Inc., announced on April 11, 2005, that
their marking name Reminyl (galantamine hydrobromide) would be changed
to Razadyne in activity to FDA reports of prescribing and dispensing
errors due to compounding of the names Reminyl and the diabetes drug
Amaryl (glimepiride), which is marketed by Sanofi-Aventis.

Oct.
26, 2004 — The U.S.
Food and Drug Governing (FDA), Janssen Pharmaceutica Products, LP, and
Samuel Johnson & Lyndon Baines Johnson Pharmaceutical Investigation
and Melioration, LLC, have warned physicians, pharmacists, and other
healthcare professionals via accolade of reports of medicine errors
involving muddiness between galantamine hydrobromide (Reminyl, made by
Janssen/J&J) and glimepiride (Amaryl, made by Aventis
Pharmaceuticals, Inc.), according to a prophylactic device preparedness
sent present from MedWatch, the FDA’s preventive noesis and adverse
case reporting platform.

The
medicinal drug errors included instances of glimepiride fluctuation for
prescribed galantamine.
Incorrect dispensing and giving medication of glimepiride led to
various participant role adverse events, including severe hypoglycemia
and one dying.

Galantamine
is indicated in the direction of mild to moderate Alzheimer’s-type
dementia, and glimepiride is indicated in the discussion of
non–insulin-dependent type 2 diabetes mellitus.

According to the
letter of the alphabet, prescriptions have been incorrectly written,
interpreted, labeled, and/or filled due to mark name Gestalt law of
organization, overlapping dose enduringness (4 mg) and form (tablet),
and wine names that may lead to their proximal memory board.

This is a part of article Amaryl Substituted for Reminyl Causes Hypoglycemia. Part 1 Taken from "Generic Amaryl (Glimepiride) Information" Information Blog

Labels: pharmacology

# posted by Haig Aglaia @ 2:41 PM